Sabrina Serani is a senior editor for Targeted Oncology.
mRNA-4157 Plus Pembrolizumab Continues to Improve RFS in High-Risk Melanoma
December 18th 2023Findings from 3-year follow-up of KEYNOTE-942/mRNA-4157-P201 show that the cancer vaccine mRNA-4157 plus pembrolizumab reduced the risk of recurrence or death in patients with stage III/IV melanoma following resection.
Survival in EGFR+ NSCLC Improves With Anlotinib/Icotinib
December 16th 2023Anlotinib, a novel multi-targeting tyrosine kinase inhibitor, and icotinib, a first-generation EGFR TKI, demonstrated efficacy and tolerability in the first line for the treatment of patients with EGFR-mutated advanced non–small cell lung cancer.
A New Standard of Care for Small Cell Lung Cancer?
December 12th 2023Antibody-based DLL3-targeting agents and antibody-drug conjugates present exciting treatment possibilities in small cell lung cancer, according to a presentation by Charles Rudin, MD, at the 18th Annual New York Lung Cancer Symposium.
Vibostolimab/Pembrolizumab Fails to Reach Statistical Significance in NSCLC
December 8th 2023The combination of vibostolimab and pembrolizumab plus docetaxel did not significantly improve progression-free survival compared with docetaxel monotherapy in patients with previously treated metastatic non–small cell lung cancer.